

Gonasagrie Nair

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10796446/publications.pdf>

Version: 2024-02-01

44
papers

3,931
citations

516710

16
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

3696
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	4.0	35
2	Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	2.1	1
3	Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. <i>Lancet</i> , The, 2022, 399, 1779-1789.	13.7	177
4	Electronic consent in a COVID-19 vaccine implementation trial in South Africa: Participant perspectives. <i>South African Journal of Science</i> , 2022, 118, .	0.7	0
5	High HIV incidence among young women in South Africa: Data from a large prospective study. <i>PLoS ONE</i> , 2022, 17, e0269317.	2.5	4
6	Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 513-520.	5.8	22
7	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , the, 2021, 8, e87-e95.	4.7	70
8	Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. <i>AIDS and Behavior</i> , 2021, 25, 2430-2440.	2.7	17
9	Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa. <i>BMC Women's Health</i> , 2021, 21, 175.	2.0	1
10	Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. <i>EClinicalMedicine</i> , 2021, 34, 100800.	7.1	12
11	The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. <i>AIDS and Behavior</i> , 2021, 25, 4169-4179.	2.7	5
12	Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	1.9	2
13	Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study. <i>Lancet HIV</i> , the, 2021, 8, e495-e501.	4.7	16
14	Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 760504.	4.8	5
15	Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	2
16	Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial. <i>AIDS and Behavior</i> , 2020, 24, 1432-1442.	2.7	38
17	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , 2020, 34, 559-567.	2.2	3
18	Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25491.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 632-640.	1.1	1
20	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. <i>Lancet, The</i> , 2019, 394, 303-313.	13.7	230
21	Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. <i>AJOB Empirical Bioethics</i> , 2019, 10, 79-87.	1.6	3
22	Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 746-753.	1.2	0
23	Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women. <i>Journal of the International AIDS Society</i> , 2019, 22, e25257.	3.0	12
24	Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study. <i>Aids</i> , 2019, 33, 1619-1622.	2.2	3
25	Social harms in female-initiated HIV prevention method research. <i>Aids</i> , 2019, 33, 2237-2244.	2.2	11
26	Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 580-589.	2.1	32
27	Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 175-182.	2.1	9
28	Favoring "Peace of Mind": A Qualitative Study of African Women's HIV Prevention Product Formulation Preferences from the MTN-020/ASPIRE Trial. <i>AIDS Patient Care and STDs</i> , 2017, 31, 305-314.	2.5	33
29	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 330-337.	2.1	16
30	Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). <i>Sexually Transmitted Diseases</i> , 2017, 44, 135-140.	1.7	11
31	HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. <i>PLoS ONE</i> , 2017, 12, e0178594.	2.5	4
32	An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 333-343.	2.1	123
33	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	27.0	624
34	Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 212-217.	2.1	34
35	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. <i>PLoS ONE</i> , 2015, 10, e0128857.	2.5	25
36	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2015, 372, 509-518.	27.0	1,094

#	ARTICLE	IF	CITATIONS
37	Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. <i>Lancet HIV</i> , 2015, 2, e279-e287.	4.7	43
38	Prevalent and Incident Gonorrhoea and Chlamydia Infections among Oral Contraceptive and Depot Medroxyprogesterone Acetate Users in MTN-003 (VOICE). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A278-A278.	1.1	1
39	Long-term Follow-up of HIV Seroconverters from the VOICE Trial - An Analysis of Data from MTN-015. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A93-A93.	1.1	1
40	Changes to Antiretroviral Drug Regimens during Integrated TB+HIV Treatment: Results of the Sapit Trial. <i>Antiviral Therapy</i> , 2014, 19, 161-169.	1.0	16
41	Feasibility, Performance, and Acceptability of the Wisebag [®] for Potential Monitoring of Daily Gel Applicator Use in Durban, South Africa. <i>AIDS and Behavior</i> , 2013, 17, 640-648.	2.7	17
42	The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPiT Trial. <i>Annals of Internal Medicine</i> , 2012, 157, 313.	3.9	101
43	Integration of Antiretroviral Therapy with Tuberculosis Treatment. <i>New England Journal of Medicine</i> , 2011, 365, 1492-1501.	27.0	451
44	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. <i>New England Journal of Medicine</i> , 2010, 362, 697-706.	27.0	608